[18], in their randomised controlled trial, strengthened these findings by illustrating the profound effect of GLP‐1 RAs in reducing biomarkers of nonalcoholic steatohepatitis. This evidence concerns the gene GCG and metabolic dysfunction-associated steatohepatitis.